Stock News

Analysts See $-0.28 EPS for FibroGen, Inc. (FGEN); Shorts at NEAH POWER SYSTEMS NEW (NPWZ) Raised By 143.98%

Analysts expect FibroGen, Inc. (NASDAQ:FGEN) to report $-0.28 EPS on March, 7.They anticipate $0.26 EPS change or 48.15% from last quarter’s $-0.54 EPS. After having $-0.50 EPS previously, FibroGen, Inc.’s analysts see -44.00% EPS growth. The stock decreased 0.59% or $0.3 during the last trading session, reaching $50.7. About 852,809 shares traded or 41.14% up from the average. FibroGen, Inc. (NASDAQ:FGEN) has risen 52.86% since February 10, 2017 and is uptrending. It has outperformed by 36.16% the S&P500.

NEAH POWER SYSTEMS NEW (OTCMKTS:NPWZ) had an increase of 143.98% in short interest. NPWZ’s SI was 439,900 shares in February as released by FINRA. Its up 143.98% from 180,300 shares previously. With 5.37M avg volume, 0 days are for NEAH POWER SYSTEMS NEW (OTCMKTS:NPWZ)’s short sellers to cover NPWZ’s short positions. It closed at $0.0006 lastly. It is down 0.00% since February 10, 2017 and is . It has underperformed by 16.70% the S&P500.

Neah Power Systems, Inc. develops and sells renewable energy solutions using direct methanol micro fuel cell technology for the military, transportation vehicle, and portable electronics applications. The company has market cap of $1.35 million. The firm develops fuel cells, including PowerChip and BuzzCell products. It currently has negative earnings. It is also involved in developing Formira HOD, a reformer platform for direct on-site generation of hydrogen gas.

FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States. The company has market cap of $4.16 billion. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It currently has negative earnings. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.

Among 8 analysts covering FibroGen Inc (NASDAQ:FGEN), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. FibroGen Inc had 16 analyst reports since July 29, 2015 according to SRatingsIntel. The company was maintained on Tuesday, August 8 by Jefferies. Leerink Swann maintained FibroGen, Inc. (NASDAQ:FGEN) on Tuesday, August 8 with “Buy” rating. The firm earned “Neutral” rating on Thursday, January 21 by Credit Suisse. On Friday, July 21 the stock rating was downgraded by Goldman Sachs to “Neutral”. The firm has “Buy” rating given on Friday, December 4 by Citigroup. Credit Suisse upgraded FibroGen, Inc. (NASDAQ:FGEN) on Thursday, February 11 to “Outperform” rating. On Sunday, September 10 the stock rating was maintained by Stifel Nicolaus with “Buy”. The firm earned “Buy” rating on Wednesday, October 18 by Stifel Nicolaus. The company was maintained on Monday, August 14 by Jefferies. The rating was initiated by Lake Street on Wednesday, September 23 with “Hold”.

Leave a Reply

Your email address will not be published. Required fields are marked *